Tim E. Hawkins

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Blood · 2014 · 638 citations · Full text

Life Sciences, Immunology, Internal Medicine +3

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Journal of Clinical Oncology · 2019 · 307 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Immunological Development and Cardiovascular Function Are Normal in Annexin VI Null Mutant Mice

Tim E. Hawkins, Jürgen Roes, Daryl D. Rees et al. · Molecular and Cellular Biology · 1999 · 71 citations

Life Sciences, Genetics, Physiology +15

Altered mechanical properties and intracellular calcium signaling in cardiomyocytes from annexin 6 null‐mutant mice

Guojie Song, Siân E. Harding, Michael R. Duchen et al. · The FASEB Journal · 2002 · 60 citations

Life Sciences, Cell Biology, Physiology +17

Annexin 5 mediates a peroxide-induced Ca2+ influx in B cells

Helmut Kubista, Tim E. Hawkins, Darshana Patel et al. · Current Biology · 1999 · 59 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +9